Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 232

1.

[An important supplement to my article].

Dingermann T.

Z Rheumatol. 2017 Aug;76(6):553. doi: 10.1007/s00393-017-0336-y. German. No abstract available.

PMID:
28795189
2.

New Knowledge About Old Drugs: The Anti-Inflammatory Properties of Cardiac Glycosides.

Fürst R, Zündorf I, Dingermann T.

Planta Med. 2017 Aug;83(12-13):977-984. doi: 10.1055/s-0043-105390. Epub 2017 Mar 15. Review.

PMID:
28297727
3.

High thioredoxin-1 levels in rheumatoid arthritis patients diminish binding and signalling of the monoclonal antibody Tregalizumab.

Heim K, Dälken B, Faust S, Rharbaoui F, Engling A, Wallmeier H, Dingermann T, Radeke HH, Schüttrumpf J, Gutscher M.

Clin Transl Immunology. 2016 Dec 23;5(12):e121. doi: 10.1038/cti.2016.69. eCollection 2016 Dec.

4.

Biosimilars Are Here: A Hospital Pharmacist's Guide to Educating Health Care Professionals on Biosimilars.

Jarrett S, Dingermann T.

Hosp Pharm. 2015 Nov;50(10):884-893. Epub 2015 Nov 19.

5.

Biosimilar epoetin zeta: extrapolation of indications and real world utilization experience.

Dingermann T, Scotte F.

Expert Opin Biol Ther. 2016 Jul;16(7):967-74. doi: 10.1080/14712598.2016.1194822. Review.

PMID:
27227424
6.

A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway.

Helling B, König M, Dälken B, Engling A, Krömer W, Heim K, Wallmeier H, Haas J, Wildemann B, Fritz B, Jonuleit H, Kubach J, Dingermann T, Radeke HH, Osterroth F, Uherek C, Czeloth N, Schüttrumpf J.

Immunol Cell Biol. 2015 Apr;93(4):396-405. doi: 10.1038/icb.2014.102. Epub 2014 Dec 16.

7.

PEGylation--a well-proven strategy for the improvement of recombinant drugs.

Zündorf I, Dingermann T.

Pharmazie. 2014 May;69(5):323-6. Review.

PMID:
24855821
8.

The MLL recombinome of acute leukemias in 2013.

Meyer C, Hofmann J, Burmeister T, Gröger D, Park TS, Emerenciano M, Pombo de Oliveira M, Renneville A, Villarese P, Macintyre E, Cavé H, Clappier E, Mass-Malo K, Zuna J, Trka J, De Braekeleer E, De Braekeleer M, Oh SH, Tsaur G, Fechina L, van der Velden VH, van Dongen JJ, Delabesse E, Binato R, Silva ML, Kustanovich A, Aleinikova O, Harris MH, Lund-Aho T, Juvonen V, Heidenreich O, Vormoor J, Choi WW, Jarosova M, Kolenova A, Bueno C, Menendez P, Wehner S, Eckert C, Talmant P, Tondeur S, Lippert E, Launay E, Henry C, Ballerini P, Lapillone H, Callanan MB, Cayuela JM, Herbaux C, Cazzaniga G, Kakadiya PM, Bohlander S, Ahlmann M, Choi JR, Gameiro P, Lee DS, Krauter J, Cornillet-Lefebvre P, Te Kronnie G, Schäfer BW, Kubetzko S, Alonso CN, zur Stadt U, Sutton R, Venn NC, Izraeli S, Trakhtenbrot L, Madsen HO, Archer P, Hancock J, Cerveira N, Teixeira MR, Lo Nigro L, Möricke A, Stanulla M, Schrappe M, Sedék L, Szczepański T, Zwaan CM, Coenen EA, van den Heuvel-Eibrink MM, Strehl S, Dworzak M, Panzer-Grümayer R, Dingermann T, Klingebiel T, Marschalek R.

Leukemia. 2013 Nov;27(11):2165-76. doi: 10.1038/leu.2013.135. Epub 2013 Apr 30.

9.

[The AMNOG and its consequences].

Dingermann T.

Internist (Berl). 2013 Jun;54(6):769-74. doi: 10.1007/s00108-013-3247-2. German.

PMID:
23475259
10.

[Molecular copies of off-patent biologics that have become biosimilars: a new group recombinant products].

Dingermann T, Zündorf I.

Pharm Unserer Zeit. 2012 Nov;41(6):446-52. Review. German. No abstract available.

PMID:
23362547
11.

[White, brown or beige rather?].

Zündorf I, Dingermann T.

Pharm Unserer Zeit. 2012 Nov;41(6):443-4. German. No abstract available.

PMID:
23362546
12.

[Coming soon: the pill for men?].

Zündorf I, Dingermann T.

Pharm Unserer Zeit. 2012 Nov;41(6):442-3. German. No abstract available.

PMID:
23362545
13.

Secondary mutations in t(4;11) leukemia patients.

Prelle C, Bursen A, Dingermann T, Marschalek R.

Leukemia. 2013 Jun;27(6):1425-7. doi: 10.1038/leu.2012.365. Epub 2012 Dec 14. No abstract available.

14.

[Editorial: Pharmazie in unserer Zeit 6/2012].

Dingermann T.

Pharm Unserer Zeit. 2012 Nov;41(6):439. doi: 10.1002/pauz.201290096. German. No abstract available.

PMID:
23124574
15.

[Which herbal drugs can be trusted? Herbal drugs increasingly from the supermarket (interview by Dr. med. Dirk Einecke)].

Dingermann T.

MMW Fortschr Med. 2012 Jun 21;O 154 Suppl 2:24. German. No abstract available.

PMID:
22916421
16.

[Leukemia: A highly malignant disease].

Marschalek R, Zündorf I, Dingermann T.

Pharm Unserer Zeit. 2012 May;41(3):186-9. Review. German. No abstract available.

PMID:
22844664
17.

[Fitness for Couch-Potatoes? ].

Zündorf I, Dingermann T.

Pharm Unserer Zeit. 2012 May;41(3):183-4. German. No abstract available.

PMID:
22844663
18.

[Editorial: Pharmazie in unserer Zeit 4/2012].

Dingermann T, Schubert-Zsilavecz M, Schulz M.

Pharm Unserer Zeit. 2012 Jul;41(4):267. doi: 10.1002/pauz.201290064. German. No abstract available.

PMID:
22753113
19.

[Pharmazie in unserer Zeit 3/2012].

Marschalek R, Dingermann T.

Pharm Unserer Zeit. 2012 May;41(3):179. doi: 10.1002/pauz.201290042. German. No abstract available.

PMID:
22549645
20.

Ein Pockenvirus gegen Tumorzellen.

Linder A, Marino G, Prechtel J, Rest D, Sabatino F, Zündorf I, Dingermann T.

Pharm Unserer Zeit. 2012 Mar;41(2):106-7. doi: 10.1002/pauz.201290022. German. No abstract available.

PMID:
24523076
21.

Editorial: Pharmazie in unserer Zeit 2/2012.

Dingermann T, Stein J.

Pharm Unserer Zeit. 2012 Mar;41(2):103. doi: 10.1002/pauz.201290020. German. No abstract available.

PMID:
24523075
22.

Do non-genomically encoded fusion transcripts cause recurrent chromosomal translocations?

Kowarz E, Dingermann T, Marschalek R.

Cancers (Basel). 2012 Oct 18;4(4):1036-49. doi: 10.3390/cancers4041036.

23.

A complex MLL rearrangement identified five years after initial MDS diagnosis results in out-of-frame fusions without progression to acute leukemia.

Meyer C, Kowarz E, Yip SF, Wan TS, Chan TK, Dingermann T, Chan LC, Marschalek R.

Cancer Genet. 2011 Oct;204(10):557-62. doi: 10.1016/j.cancergen.2011.10.001.

PMID:
22137486
24.

[Organ transplantation--from swine?].

Dingermann T, Zündorf I.

Pharm Unserer Zeit. 2011 Nov;40(6):451-3. doi: 10.1002/pauz.201190072. Review. German. No abstract available.

PMID:
22028126
25.

[What is HUSEC041 MLST ST678?].

Winckler T, Dingermann T, Zündorf I.

Pharm Unserer Zeit. 2011 Jul;40(4):355-6. doi: 10.1002/pauz.201190043. German. No abstract available.

PMID:
21698638
26.

["Demarcation issues" - an unusual subject in Pharmazie in unserer Zeit? Not at all!].

Knöss W, Dingermann T.

Pharm Unserer Zeit. 2011 Jul;40(4):293. doi: 10.1002/pauz.201190036. German. No abstract available.

PMID:
21695705
27.

[The new (threatening?) influenza pandemics].

Zündorf I, Dingermann T.

Pharm Unserer Zeit. 2011 Mar;40(2):120-5. Review. German. No abstract available.

PMID:
21630537
28.

[Vascular damage in cancer therapy].

Berger S, Bourdy S, Hergaden B, Schmitt J, Zündorf I, Dingermann T.

Pharm Unserer Zeit. 2011 Mar;40(2):101-2. German. No abstract available.

PMID:
21630533
29.

An alternative to animal testing in the quality control of erythropoietin.

Zimmermann H, Gerhard D, Hothorn LA, Dingermann T.

Pharmeur Bio Sci Notes. 2011 Jun;2011(1):66-80.

PMID:
21619857
30.

The heterodimerization domains of MLL-FYRN and FYRC--are potential target structures in t(4;11) leukemia.

Pless B, Oehm C, Knauer S, Stauber RH, Dingermann T, Marschalek R.

Leukemia. 2011 Apr;25(4):663-70. doi: 10.1038/leu.2010.308. Epub 2011 Jan 14.

PMID:
21233834
31.

[Alfa-interferons. Genetically engineered Antivirals].

Dingermann T, Zündorf I.

Pharm Unserer Zeit. 2011 Jan;40(1):68-77. doi: 10.1002/pauz.201100402. Review. German. No abstract available.

PMID:
21194085
32.

[Will a vaccine against hepatitis E soon be available?].

Zündorf I, Dingermann T.

Pharm Unserer Zeit. 2011 Jan;40(1):44. doi: 10.1002/pauz.201090112. German. No abstract available.

PMID:
21194081
33.

[SiRNA against hepatitis C?].

Zündorf I, Dingermann T.

Pharm Unserer Zeit. 2011 Jan;40(1):10-1. doi: 10.1002/pauz.201090107. German. No abstract available.

PMID:
21194075
34.

[Editorial: Pharmazie in unserer Zeit 1/2011].

Dingermann T, Zeuzem S.

Pharm Unserer Zeit. 2011 Jan;40(1):3. doi: 10.1002/pauz.201090111. German. No abstract available.

PMID:
21194071
35.

Premature transcript termination, trans-splicing and DNA repair: a vicious path to cancer.

Kowarz E, Merkens J, Karas M, Dingermann T, Marschalek R.

Am J Blood Res. 2011;1(1):1-12. Epub 2011 Apr 7.

36.

The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures.

Benedikt A, Baltruschat S, Scholz B, Bursen A, Arrey TN, Meyer B, Varagnolo L, Müller AM, Karas M, Dingermann T, Marschalek R.

Leukemia. 2011 Jan;25(1):135-44. doi: 10.1038/leu.2010.249. Epub 2010 Oct 29.

PMID:
21030982
37.

[ Editorial. Pharmazie in unserer Zeit 5/2010].

Dingermann T, Schubert-Zsilavecz M.

Pharm Unserer Zeit. 2010 Sep;39(5):331. doi: 10.1002/pauz.201090072. German. No abstract available.

PMID:
20818677
38.

Transcriptional properties of human NANOG1 and NANOG2 in acute leukemic cells.

Eberle I, Pless B, Braun M, Dingermann T, Marschalek R.

Nucleic Acids Res. 2010 Sep;38(16):5384-95. doi: 10.1093/nar/gkq307. Epub 2010 Apr 28.

39.

[The deciphering of the fifth DNA base. The human methylome].

Winckler T, Zündorf I, Dingermann T.

Pharm Unserer Zeit. 2010 May;39(3):210-6. doi: 10.1002/pauz.201000368. Review. German. No abstract available.

PMID:
20425775
40.

[Editorial].

Dingermann T, Jung M, Sippl W.

Pharm Unserer Zeit. 2010 May;39(3):167. doi: 10.1002/pauz.201090023. German. No abstract available.

PMID:
20425768
41.

[Antisense against cancer?]].

Edris E, Möller AM, Oberhauser EM, Zündorf I, Dingermann T.

Pharm Unserer Zeit. 2010 May;39(3):170-1. doi: 10.1002/pauz.201090025. German. No abstract available.

PMID:
20425764
42.

[Antibodies instead of insulin?].

Anders S, Kühnemund L, Stauch M, Zündorf I, Dingermann T.

Pharm Unserer Zeit. 2010 Mar;39(2):97-8. doi: 10.1002/pauz.201090017. German. No abstract available.

PMID:
20196056
43.

The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4.

Bursen A, Schwabe K, Rüster B, Henschler R, Ruthardt M, Dingermann T, Marschalek R.

Blood. 2010 Apr 29;115(17):3570-9. doi: 10.1182/blood-2009-06-229542. Epub 2010 Mar 1.

PMID:
20194896
44.

[Nobel Prize in Chemistry: Winning assembly line workers].

Zündorf I, Dingermann T.

Pharm Unserer Zeit. 2010;39(1):8-9. doi: 10.1002/pauz.200990125. German. No abstract available.

PMID:
20033956
45.

[Nobel Prize in Physiology and Medicine: famous endings].

Zündorf I, Dingermann T.

Pharm Unserer Zeit. 2010;39(1):6-7. doi: 10.1002/pauz.200990113. German. No abstract available.

PMID:
20033951
46.

[Tea drinking against malaria?].

Dingermann T.

Pharm Unserer Zeit. 2009;38(6):491. doi: 10.1002/pauz.200990105. German. No abstract available.

PMID:
19862712
47.

Statistical aspects of design and validation of microtitre-plate-based linear and non-linear parallel in vitro bioassays.

Zimmermann H, Gerhard D, Dingermann T, Hothorn LA.

Biotechnol J. 2010 Jan;5(1):62-74. doi: 10.1002/biot.200900146.

PMID:
19844917
48.

[Please a BiTE!].

Freitag H, Gress G, Messer K, Sivaz G, Weinbender O, Zündorf I, Dingermann T.

Pharm Unserer Zeit. 2009;38(5):396-8. doi: 10.1002/pauz.200990069. German. No abstract available.

PMID:
19711314
49.

[ Editorial: Pharmazie in unserer Zeit 5/2009].

Dingermann T, Schubert-Zsilavecz M.

Pharm Unserer Zeit. 2009;38(5):391. doi: 10.1002/pauz.200990065. German. No abstract available.

PMID:
19711307
50.

Lycopsamine and cumambrin B from Eupatorium maculatum.

Wiedenfeld H, Hösch G, Roeder E, Dingermann T.

Pharmazie. 2009 Jun;64(6):415-6.

PMID:
19618682

Supplemental Content

Loading ...
Support Center